We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Guardant Health (GH) Q3 Earnings: Wall Street Forecasts for Key Metrics
Read MoreHide Full Article
In its upcoming report, Guardant Health (GH - Free Report) is predicted by Wall Street analysts to post quarterly loss of -$0.29 per share, reflecting an increase of 25.6% compared to the same period last year. Revenues are forecasted to be $350.83 million, representing a year-over-year increase of 32.3%.
The consensus EPS estimate for the quarter has been revised 6.9% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
In light of this perspective, let's dive into the average estimates of certain Guardant Health metrics that are commonly tracked and forecasted by Wall Street analysts.
Based on the collective assessment of analysts, 'Revenue- Oncology' should arrive at $227.79 million. The estimate points to a change of +23.5% from the year-ago quarter.
Analysts expect 'Revenue- Screening' to come in at $60.29 million. The estimate suggests a change of +150% year over year.
The consensus among analysts is that 'Revenue- Biopharma and data' will reach $60.27 million. The estimate points to a change of +10.1% from the year-ago quarter.
Analysts forecast 'Total tests performed (oncology tests)' to reach 108,860 . Compared to the present estimate, the company reported 74,000 in the same quarter last year.
Guardant Health shares have witnessed a change of +2.5% in the past month, in contrast to the Zacks S&P 500 composite's -2% move. With a Zacks Rank #3 (Hold), GH is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Countdown to Guardant Health (GH) Q3 Earnings: Wall Street Forecasts for Key Metrics
In its upcoming report, Guardant Health (GH - Free Report) is predicted by Wall Street analysts to post quarterly loss of -$0.29 per share, reflecting an increase of 25.6% compared to the same period last year. Revenues are forecasted to be $350.83 million, representing a year-over-year increase of 32.3%.
The consensus EPS estimate for the quarter has been revised 6.9% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
In light of this perspective, let's dive into the average estimates of certain Guardant Health metrics that are commonly tracked and forecasted by Wall Street analysts.
Based on the collective assessment of analysts, 'Revenue- Oncology' should arrive at $227.79 million. The estimate points to a change of +23.5% from the year-ago quarter.
Analysts expect 'Revenue- Screening' to come in at $60.29 million. The estimate suggests a change of +150% year over year.
The consensus among analysts is that 'Revenue- Biopharma and data' will reach $60.27 million. The estimate points to a change of +10.1% from the year-ago quarter.
Analysts forecast 'Total tests performed (oncology tests)' to reach 108,860 . Compared to the present estimate, the company reported 74,000 in the same quarter last year.
View all Key Company Metrics for Guardant Health here>>>Guardant Health shares have witnessed a change of +2.5% in the past month, in contrast to the Zacks S&P 500 composite's -2% move. With a Zacks Rank #3 (Hold), GH is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .